EU body sees Genzyme drug shortage until end-Sept

LONDON, April 23 (BestGrowthStock) – The European Medicines Agency said on Friday it
expected shortages of two drugs for rare diseases from Genzyme (GENZ.O: ) to last
at least until the end of September 2010, because of new manufacturing problems.

The U.S. company’s plant in the Allston neighbourhood of Boston was
temporarily closed last June following a viral contamination.

The closure led to shortages of Cerezyme, the company’s treatment for
Gaucher’s disease, and Fabrazyme, its treatment for Fabry disease. Both are rare
disorders caused by an enzyme deficiency that can lead to organ damage and

Genzyme had hoped by now to be in a position to start to meet demand. But
that goal has been delayed after a recent power outage affecting the water
system at the plant further disrupted production.

The EU agency last year put in place temporary treatment recommendations to
deal with the shortages, which it is now updating.

Rival drugmaker Shire (SHP.L: ) has benefited from the supply problems at
Genzyme due to extra demand for its drugs.

Stock Market

(Reporting by Ben Hirschler; Editing by Rupert Winchester)

EU body sees Genzyme drug shortage until end-Sept